Literature DB >> 16750668

Mesangial autoantigens in IgA nephropathy: matrix synthesis and localization.

Angela M Darvill1, Francis W Ballardie.   

Abstract

Primary IgA nephropathy, a chronic nephritis with variable prognosis, is characterized by mesangial immunoglobulin A, frequently with codeposition of other immunoglobulin isotypes and complement components accompanying matrix expansion typically preceding glomerular scarring. Glomerular immunoglobulin G, when present, is localized to the mesangial periphery found variably in repeat biopsies. IgG anti-mesangial cell autoantibodies (IgG-MESCA) in sera of patients with IgA nephropathy, specific by F(ab')(2) binding to 48- and 55-kD autoantigen(s) could account for these deposits, but their in vivo localization, and the functional role in promoting scarring is unknown. A specific monoclonal antibody raised previously to these human mesangial cell autoantigen fractions, in this study localized to similar glomerular sites, reinforcing the view that immunoglobulin G deposition in vivo is a result of antibody-autoantigen binding. The propensity for immunoglobulin G more than other isotypes to enhance inflammation prompted study of its functional role in vitro. Using cultured human mesangial cells in a complement-free tritiated glycosaminoglycan synthesis single outcome assay, purified IgG fractions from patient sera increased matrix production in a dose-dependent manner compared with controls. At a constant total IgG concentration, matrix synthesis was proportional to the titre of IgG-MESCA. Autoreactive IgG stimulated matrix synthesis when compared with controls or IgA fractions. These findings are consistent with IgG-MESCA autoantibodies enhancing mesangial matrix synthesis in vitro, which suggests that in IgA nephropathy, similar prosclerotic autoimmune mechanisms might operate. Recombinant TGFbeta(1) also induced matrix synthesis, raising the possibility that both autoimmune mechanisms and those TGFbeta(1)-dependent are functional or inter-related. The pathogenesis of glomerular scarring and loss in IgA nephropathy may include, in part, these mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750668     DOI: 10.1016/j.lab.2006.02.001

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation.

Authors:  Lisha Liu; Wen Qiu; Hui Wang; Yan Li; Jianbo Zhou; Mei Xia; Kai Shan; Rongrong Pang; Ying Zhou; Dan Zhao; Yingwei Wang
Journal:  J Biol Chem       Date:  2012-03-15       Impact factor: 5.157

Review 2.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

3.  Role of activating transcription factor 3 (ATF3) in sublytic C5b-9-induced glomerular mesangial cell apoptosis.

Authors:  Xiaoming Jiang; Jing Zhang; Mei Xia; Wen Qiu; Hui Wang; Dan Zhao; Yingwei Wang
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

4.  Clinicopathological and immunohistological features in childhood IgA nephropathy: a single-centre experience.

Authors:  Rezan Topaloglu; Dicle Orhan; Yelda Bilginer; Erdem Karabulut; Fatih Ozaltin; Ali Duzova; Gulsev Kale; Nesrin Besbas
Journal:  Clin Kidney J       Date:  2013-02-24

5.  Expression of P311, a transforming growth factor beta latency-associated protein-binding protein, in human kidneys with IgA nephropathy.

Authors:  Fengping Wang; Xisheng Xie; Junming Fan; Li Wang; Dongyang Guo; Lichuan Yang; Xiaofen Ma; Lina Zhang; Zi Li
Journal:  Int Urol Nephrol       Date:  2009-11-28       Impact factor: 2.370

6.  TSP-1 promotes glomerular mesangial cell proliferation and extracellular matrix secretion in Thy-1 nephritis rats.

Authors:  Wen Qiu; Yan Li; Jianbo Zhou; Chenhui Zhao; Jing Zhang; Kai Shan; Dan Zhao; Yingwei Wang
Journal:  J Biomed Res       Date:  2011-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.